Brainstorm cell therapeutics announces first quarter 2024 financial results and provides corporate update

Company received written agreement from the u.s. fda under a special protocol assessment (spa) on the design for a phase 3b trial of nurown® conference call planned for later this quarter to provide update on nurown program new york , may 14, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the first quarter ended march 31, 2024 and provided a corporate update. "we recently achieved an important milestone on our debamestrocel (nurown®) development program, reaching agreement with the us fda on a special protocol assessment for our planned phase 3b trial of nurown.
BCLI Ratings Summary
BCLI Quant Ranking